Effect of Exercise Training in Patients With Pulmonary Hypertension

Status Recruiting

Clinical Trial Summary

Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high healthcare costs. Earlier studies in Heidelberg, Germany showed good evidence for the effect of exercise training on improving exercise performance, quality of life and pulmonary hemodynamics in patients with pulmonary hypertension. The main objectives of the present project are: 1. to investigate the quality of the implementation of a standardized 3 week in-hospital exercise training program on markers of outcome and disease severity in PH-patients in Switzerland immediately after training and after 3 and 12 month. 2. to look whether training with hyperoxia vs. standard care might be more effective. This is a multicentre, randomized parallel-group trial where the intervention rehabilitation is delayed in one group so that they can serve as standard care controls for the others. In a nested single-centre randomized-controlled trial patent will additionally be randomized to receive either usual rehabilitation (UR) or rehabilitation with standardized supplemental oxygen therapy (SSOT) during nights and ergometer training. Patients will receive a PH specific rehabilitation program during 3 weeks followed by an instructed home-based training program for 12 weeks. Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights upon written informed consent.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02558582
Study type	Interventional
Source	University of Zurich
Contact	Silvia Ulrich Somaini, PD Dr.
Phone	0041442552220
Email	silvia.ulrich@usz.ch
Status	Recruiting
Phase	N/A
Start date	September 1, 2015
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04095286` - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants	Phase 1
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Completed	`NCT02191137` - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)	Phase 4
Completed	`NCT01959828` - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery	Phase 3
Withdrawn	`NCT01202045` - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients	N/A
Completed	`NCT00963001` - Effect of Food on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT01121458` - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed	Phase 4
Completed	`NCT00963027` - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	Phase 1
Terminated	`NCT00825266` - Insulin Resistance in Pulmonary Arterial Hypertension	Phase 4
Terminated	`NCT00384865` - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension	Phase 2
Active, not recruiting	`NCT03926572` - Acute Decompensation of Pulmonary Hypertension	N/A
Completed	`NCT02826252` - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)	N/A
Completed	`NCT02545465` - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice	N/A
Recruiting	`NCT04498299` - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Active, not recruiting	`NCT02562235` - Riociguat in Children With Pulmonary Arterial Hypertension (PAH)	Phase 3
Completed	`NCT02755298` - Chronic Clinical Effect of Acetazolamide	Phase 2/Phase 3
Completed	`NCT02576002` - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)	N/A
Terminated	`NCT03043976` - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension	N/A
Completed	`NCT01317134` - Endothelial Function in Patients With Pulmonary Arterial Hypertension	N/A
Completed	`NCT01178073` - A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	Phase 3